Test your knowledge in choosing/sequencing therapy for NSCLC
{"name":"Test your knowledge in choosing\/sequencing therapy for NSCLC", "url":"https://www.quiz-maker.com/QP2ZWQP2W","txt":"Shared decision-making involves open communication, outlining risks and benefits, and eliciting patient values., Overall response rates for patients with metastatic mutation-driven NSCLC who are treated with targeted therapies are:, A patient with metastatic KRAS-mutant NSCLC and PD-L1 of ≥50% should be treated with which of the following therapies in the second-line setting?","img":"https://www.quiz-maker.com/3012/images/ogquiz.png"}